• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?

    6/26/25 11:44:00 AM ET
    $ADCT
    $CTOR
    $ONCY
    $OSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ADCT alert in real time by email

    USA News Group News Commentary

    Issued on behalf of Oncolytics Biotech Inc.

    VANCOUVER, BC, June 26, 2025 /PRNewswire/ -- USA News Group News Commentary – With analysts forecasting the global oncology drug market to surpass US$900 billion by 2034, investor interest in cancer-focused biotechs is rapidly intensifying. ResearchAndMarkets and Vision Research Reports both point to strong double-digit growth, citing surging demand for next-gen diagnostics and immunotherapies. Yet even as market potential grows, the U.S. public health sector is facing potential setbacks. Budget proposals suggest National Cancer Institute (NCI) funding could be slashed by up to 40%, while Bloomberg highlights concerns around drug affordability and access. These headwinds are forcing a shift in expectations — placing the burden of innovation on the private sector, where companies like Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), Citius Oncology, Inc. (NASDAQ:CTOR), ADC Therapeutics SA (NYSE:ADCT), and OS Therapies Incorporated (NYSE-American: OSTX).

    The shift reflects more than a funding gap — it signals a structural realignment in how cancer breakthroughs may be brought to market. As public systems face pressure and timelines extend, nimble biotech firms are advancing targeted treatments, combination trials, and regulatory conversations once dominated by legacy institutions. Against this backdrop, market watchers see a pivotal window opening for investors willing to back the next wave of oncology innovation.

    Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) has entered a new chapter with the appointment of Jared Kelly as Chief Executive Officer and member of the Board. With a background in high-value biotech transactions and late-stage development strategy, Kelly brings experience that may help position the company for its next phase of clinical and corporate progress.

    Prior to joining Oncolytics, Kelly was General Counsel at Ambrx Biopharma, where he played a key role in the company's $2 billion acquisition by Johnson & Johnson. He also advised a range of life sciences firms on partnerships, licensing, and M&A during his tenure at Kirkland & Ellis LLP and Lowenstein Sandler LLP. His arrival comes as Oncolytics continues advancing pelareorep, a viral-based immunotherapy being evaluated in combination with checkpoint inhibitors and other agents across multiple cancer indications.

    "Pelareorep's clinical data across multiple tumors is striking and represents the potential for a true backbone immunotherapy to address many in-need indications. Importantly, the data show that pelareorep creates a robust immunologic response in difficult tumors and increases survival in a patient population where survival has historically evaded most patients," said Jared Kelly, CEO of Oncolytics Biotech. "With a renewed focus and sharpened clinical development plan, we believe we will move pelareorep forward effectively and efficiently to a place where potential partners will see the value of a de-risked immunotherapy. I am excited to get to work accelerating development and unlocking significant value for stakeholders."

    Kelly's appointment appears aligned with a focused strategy: advancing pelareorep through late-stage development while maintaining capital efficiency and openness to potential partnerships. The company's lead program continues to generate data that support further investigation across several difficult-to-treat cancers.

    Pelareorep already holds FDA Fast Track designation in two separate indications — metastatic pancreatic ductal adenocarcinoma (mPDAC) and HR+/HER2- metastatic breast cancer (mBC) — a distinction that highlights regulatory interest in its potential.

    Across clinical studies, the viral-based immunotherapy has consistently shown signs of immune activation, combinability with checkpoint inhibitors and chemotherapy, and efficacy in heavily pretreated populations.

    In mPDAC, a Phase 2 cohort from the trial has reported objective response rates (ORR) above 60% in tumor-evaluable patients, exceeding historical benchmarks for this indication. Additional analyses have noted extended two-year survival rates compared to previous benchmarks. In HR+/HER2- mBC, two randomized Phase 2 trials (IND-213 and BRACELET-1) observed overall survival trends that support continued clinical evaluation.

    Elsewhere, a Phase 2 anal cancer cohort combining pelareorep with a checkpoint inhibitor demonstrated partial or complete response rates that exceeded historical control trials for checkpoint inhibitor monotherapy, suggesting potential utility beyond the company's lead programs.

    "Mr. Kelly's vision and track record is an extraordinary fit with the standout clinical data pelareorep has generated to date," said Wayne Pisano, Chair of the Board and outgoing Interim CEO of Oncolytics. "We believe Mr. Kelly's well-documented ability to prioritize clinical program development, execute successful financings, and attract the attention of large industry peers will help maximize Oncolytics' potential to deliver transformative outcomes for patients and exceptional value for investors."

    Kelly's compensation framework includes equity-based awards and performance-linked incentives tied to future financings and strategic outcomes. The structure is designed to align leadership priorities with long-term shareholder value while reinforcing a disciplined approach to capital and partnership development.

    As multiple cohorts advance within the GOBLET study — including those in pancreatic and anal cancers backed by external funding and regulatory support — Oncolytics appears positioned to continue its progress with a blend of clinical momentum, financial flexibility, and sharpened strategic direction.

    Prior to Kelly's appointment, Oncolytics presented new data from its GOBLET trial at the 2025 ASCO Annual Meeting, highlighting pelareorep's ability to stimulate both innate and adaptive immune responses in metastatic pancreatic cancer. With fresh clinical insights and new leadership in place, the company appears positioned to advance both its scientific and strategic priorities in tandem.

    CONTINUED… Read this and more news for Oncolytics Biotech at:  https://usanewsgroup.com/2023/10/02/the-most-undervalued-oncolytics-company-on-the-nasdaq/ 

    In other recent industry developments and happenings in the market include:

    Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) has entered into a strategic partnership with Fosun Pharma to accelerate development of TEV-56278, a novel anti-PD1-IL2 immunotherapy designed using its proprietary ATTENUKINE™ technology.

    "This partnership with Fosun Pharma in the development of our internally developed TEV-56278, an anti-PD1-IL2 ATTENUKINE therapy with the potential to treat devastating cancers, is the latest advance to ensuring acceleration of our pipeline," said Eric Hughes, MD, PhD, Executive Vice President, Teva Global R&D and Chief Medical Officer. "TEV-56278 demonstrates the strength of Teva's innovative drug development capabilities and how strategic partnerships with companies such as Fosun Pharma play a pivotal role in advancing therapies on behalf of patients."

    This investigational fusion protein is aimed at selectively delivering IL-2 to PD-1+ T cells, potentially enhancing anti-tumor response while limiting toxic side effects. Under the agreement, Fosun will lead clinical, manufacturing, and commercial activity in China and parts of Southeast Asia, while Teva retains global rights elsewhere.

    Citius Oncology, Inc. (NASDAQ:CTOR) recently announced that it expects to commercially launch LYMPHIR™ in 2025 for the treatment of relapsed or refractory cutaneous T-cell lymphoma (CTCL), pending FDA approval.

    "We've made steady and meaningful progress toward commercialization over the past several months," said Leonard Mazur, Chairman and CEO of Citius Oncology and Citius Pharma. "With our supply chain secured, market access supported, and no anticipated impediments to reimbursement, we are encouraged by the momentum we've built. These efforts are pivotal as we transition into a commercial-stage company and believe the planned 2025 launch of LYMPHIR has the potential to be an important inflection point for both the company and the CTCL community."

    ADC Therapeutics SA (NYSE:ADCT) recently reported updated Phase 2 data from an investigator-initiated trial of ZYNLONTA® in relapsed/refractory marginal zone lymphoma (r/r MZL), showing an 84.6% overall response rate and a 69.2% complete response rate.

    "Based on the updated Phase 2 IIT data to be shared at ICML, we are encouraged by the potential opportunity in r/r MZL and look forward to seeing additional data, as the trial expands to other sites." said Mohamed Zaki, MD, PhD, Chief Medical Officer of ADC Therapeutics. "As this trial progresses, assuming the results continue to be positive, we plan to potentially pursue a regulatory pathway and compendia in parallel as soon as sufficient data are available."

    The trial also showed encouraging durability, with complete responses maintained in 17 of the 18 patients who achieved a complete response and progression-free survival of 92.9% at 12 months. ZYNLONTA was generally well tolerated, with safety findings consistent with its existing clinical profile.

    OS Therapies Incorporated (NYSE-American: OSTX) received positive written feedback from the FDA following a Type D meeting regarding its lead candidate, OST-HER2, for pediatric lung metastatic osteosarcoma.

    "We are pleased with the feedback we received from the FDA regarding the use of external control comparators in settings where placebo-controlled randomization trials are not feasible – particularly in rare pediatric diseases such as the indication treated by OST-HER2 ," said Dr. Robert Petit, Chief Medical & Scientific Officer of OS Therapies. "Moreover, we received additional collaborative input regarding suggested statistical methods as we seek to compare OST-HER2 active treatment with external control arm(s) to support a Biologics Licensing Application (BLA) via the Accelerated Approval Program. Taken together, the feedback gives us insight on the FDA's current position and allows us to be fully prepared for the End of Phase 2 Meeting."

    The agency supported the company's proposed use of external comparators in its Phase 2b trial, potentially laying groundwork for accelerated approval. OS Therapies has submitted requests for an End of Phase 2 Meeting and Breakthrough Therapy Designation, with regulatory filings expected to advance in late 2025.

    Source: https://usanewsgroup.com/2024/09/21/is-oncolytics-biotech-the-markets-most-undervalued-cancer-opportunity/ 

    CONTACT:

    USA NEWS GROUP

    [email protected]

    (604) 265-2873

    DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles.

    While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

    Video - https://www.youtube.com/watch?v=kawrtZfPysQ

    Logo - https://mma.prnewswire.com/media/2603685/5390335/USA_News_Group_Logo.jpg

    USA News Group logo (PRNewsfoto/USA News Group)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/the-900-billion-question-who-will-deliver-the-next-cancer-breakthrough-302492478.html

    SOURCE USA News Group

    Get the next $ADCT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADCT
    $CTOR
    $ONCY
    $OSTX

    CompanyDatePrice TargetRatingAnalyst
    Citius Oncology Inc.
    $CTOR
    9/23/2025$6.00Hold → Buy
    Maxim Group
    Oncolytics Biotech Inc.
    $ONCY
    8/13/2025$7.00Buy
    Lake Street
    Teva Pharmaceutical Industries Limited
    $TEVA
    6/6/2025$24.00Buy
    Goldman
    Teva Pharmaceutical Industries Limited
    $TEVA
    5/28/2025$25.00Buy
    Truist
    Teva Pharmaceutical Industries Limited
    $TEVA
    5/12/2025$23.00Neutral → Overweight
    Analyst
    OS Therapies Incorporated
    $OSTX
    4/2/2025$19.00Buy
    Lake Street
    Citius Oncology Inc.
    $CTOR
    11/27/2024$3.00Buy
    Maxim Group
    ADC Therapeutics SA
    $ADCT
    11/8/2024$6.00Overweight
    Stephens
    More analyst ratings

    $ADCT
    $CTOR
    $ONCY
    $OSTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Chief Legal Officer Mcavoy David R. bought $20,988 worth of Ordinary Shares (1,113 units at $18.86), increasing direct ownership by 9% to 13,027 units (SEC Form 4)

    4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)

    9/9/25 4:02:56 PM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Redmile Group, Llc bought $609,000 worth of shares (200,000 units at $3.04) (SEC Form 4)

    4 - ADC Therapeutics SA (0001771910) (Issuer)

    12/13/24 9:00:14 PM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Redmile Group, Llc bought $2,248,000 worth of shares (800,000 units at $2.81) (SEC Form 4)

    4 - ADC Therapeutics SA (0001771910) (Issuer)

    7/3/24 8:00:13 PM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADCT
    $CTOR
    $ONCY
    $OSTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Czuczman Myron was granted 825,000 shares (SEC Form 4)

    4 - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)

    9/23/25 4:10:20 PM ET
    $CTOR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Mazur Leonard L was granted 1,700,000 shares (SEC Form 4)

    4 - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)

    9/23/25 4:10:23 PM ET
    $CTOR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Secretary Holubiak Myron Z was granted 950,000 shares (SEC Form 4)

    4 - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)

    9/23/25 4:10:26 PM ET
    $CTOR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADCT
    $CTOR
    $ONCY
    $OSTX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for ZYNLONTA issued to ADC Therapeutics SA

    Submission status for ADC Therapeutics SA's drug ZYNLONTA (SUPPL-5) with active ingredient LONCASTUXIMAB TESIRINE-LPYL has changed to 'Approval' on 10/12/2022. Application Category: BLA, Application Number: 761196, Application Classification:

    10/13/22 1:04:01 PM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for ZYNLONTA issued to ADC Therapeutics SA

    Submission status for ADC Therapeutics SA's drug ZYNLONTA (SUPPL-4) with active ingredient LONCASTUXIMAB TESIRINE-LPYL has changed to 'Approval' on 10/12/2022. Application Category: BLA, Application Number: 761196, Application Classification:

    10/13/22 1:03:14 PM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for ZYNLONTA issued to ADC Therapeutics SA

    Submission status for ADC Therapeutics SA's drug ZYNLONTA (ORIG-1) with active ingredient LONCASTUXIMAB TESIRINE-LPYL has changed to 'Approval' on 04/23/2021. Application Category: BLA, Application Number: 761196, Application Classification:

    4/23/21 1:46:03 PM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADCT
    $CTOR
    $ONCY
    $OSTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Teva Releases Q3 2025 Aide Memoire

    TEL AVIV, Israel, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q3 2025 Aide Memoire is available on the "Investors" page on its website. Q3 2025 Aide Memoire Teva has prepared this document to assist in the financial modeling of its quarterly results. The document is based on Teva's prior results, management's previous commentary about Teva's business outlook and data from select independent sources. About Teva Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva's commitment has nev

    9/25/25 4:30:00 PM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5, 2025

    TEL AVIV, Israel, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its third quarter 2025 financial results on Wednesday, November 5, 2025, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of the call will be available on Teva's website at: https://ir.tevapharm.com/Events-and-Presentations. Following the conclusion of the call, a replay of the webc

    9/25/25 4:30:00 PM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Patients Taking AUSTEDO XR® (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction

    Of the 209 patients with tardive dyskinesia (TD) that were surveyed, >94% reported movement improvement once treated with AUSTEDO XR® (deutetrabenazine) extended-release tabletsPatients reported high satisfaction (>89%) with AUSTEDO XR, with 96% expressing interest in continuing treatmentAlmost all (>96%) patients relayed that AUSTEDO XR was easy to take PARSIPPANY, N.J. and TEL AVIV, Israel, Sept. 20, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of data from a real-world survey of patients taking AUSTEDO XR® (deutetrabenazine) extended-release tablets. Patients taking AUST

    9/20/25 10:16:00 PM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADCT
    $CTOR
    $ONCY
    $OSTX
    SEC Filings

    View All

    SEC Form DEF 14A filed by Citius Oncology Inc.

    DEF 14A - CITIUS ONCOLOGY, INC. (0001851484) (Filer)

    9/26/25 4:30:39 PM ET
    $CTOR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Citius Oncology Inc.

    S-8 - CITIUS ONCOLOGY, INC. (0001851484) (Filer)

    9/19/25 5:12:16 PM ET
    $CTOR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citius Oncology Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Leadership Update, Financial Statements and Exhibits

    8-K - CITIUS ONCOLOGY, INC. (0001851484) (Filer)

    9/19/25 5:00:51 PM ET
    $CTOR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADCT
    $CTOR
    $ONCY
    $OSTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citius Oncology upgraded by Maxim Group with a new price target

    Maxim Group upgraded Citius Oncology from Hold to Buy and set a new price target of $6.00

    9/23/25 7:47:11 AM ET
    $CTOR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lake Street initiated coverage on Oncolytics Biotech with a new price target

    Lake Street initiated coverage of Oncolytics Biotech with a rating of Buy and set a new price target of $7.00

    8/13/25 8:42:12 AM ET
    $ONCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman initiated coverage on Teva Pharma with a new price target

    Goldman initiated coverage of Teva Pharma with a rating of Buy and set a new price target of $24.00

    6/6/25 8:33:51 AM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADCT
    $CTOR
    $ONCY
    $OSTX
    Leadership Updates

    Live Leadership Updates

    View All

    Amid NCI Budget Fears, Emerging Oncology Stocks Gain Attention

    Equity Insider News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, July 8, 2025 /PRNewswire/ -- Equity Insider News Commentary – As cancer rates climb and drug costs continue to soar, pressure is mounting on the private sector to drive innovation. Now, cancer experts are alarmed over a "gut wrenching" plan from the U.S. government to cut nearly 40% of National Cancer Institute funding, even as the price of oncology treatments pushes new limits—raising urgent concerns about access and affordability. In this shifting landscape, investors are turning their attention to a new wave of biotechs and specialty care providers developing breakthrough therapies and smarter care mo

    7/8/25 10:25:00 AM ET
    $CELC
    $CTOR
    $EXEL
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)

    Oncology Innovation Just Hit a Turning Point -- Here's What to Watch

    USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 30, 2025 /PRNewswire/ -- USA News Group News Commentary – The oncology landscape is being pulled in two directions. On one hand, U.S. cancer death rates continue to decline. On the other, global cases are expected to rise sharply—while early-onset diagnoses in younger patients are climbing at a troubling pace. At the same time, proposed federal budget cuts threaten to slash funding for the National Cancer Institute by up to 40%, raising concerns about the future of publicly funded research. With public resources under pressure, much of the innovation burden is shifting to the private sector, where a

    6/30/25 11:02:00 AM ET
    $ARAY
    $CLRB
    $ERAS
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)

    Oncolytics Biotech® Appoints Former Ambrx Executive as Chief Business Officer to Drive Business Development Strategy

    SAN DIEGO and CALGARY, Alberta, June 30, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced the appointment of Andrew Aromando as Chief Business Officer. Mr. Aromando most recently served as Chief Operating Officer at Ambrx Biopharma, where his contributions were instrumental in the $2 billion acquisition of the San Diego-based biotech by Johnson & Johnson. In his role at Oncolytics, Mr. Aromando will be responsible for leading global business development. He will a

    6/30/25 7:00:00 AM ET
    $ONCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADCT
    $CTOR
    $ONCY
    $OSTX
    Financials

    Live finance-specific insights

    View All

    Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5, 2025

    TEL AVIV, Israel, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its third quarter 2025 financial results on Wednesday, November 5, 2025, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of the call will be available on Teva's website at: https://ir.tevapharm.com/Events-and-Presentations. Following the conclusion of the call, a replay of the webc

    9/25/25 4:30:00 PM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed

    Through Week 56 in the SOLARIS trial, there were no suspected or confirmed post-injection delirium/sedation syndrome (PDSS) events observed with olanzapine LAI (TEV-'749) and its long-term systemic safety profile was consistent with other olanzapine formulations1Additional new data comparing initiation of UZEDY® (risperidone) versus Invega Sustenna® (paliperidone palmitate) in hospitalized patients found that UZEDY was associated with shorter length of stay and was preferred overall by HCPs due to its dosing characteristics and ease of use1Teva is committed to researching and developing innovative medicines that help address unmet needs for individuals living with complex mental health condi

    9/20/25 10:15:00 PM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-'749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting

    TEL AVIV, Israel, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced plans to present data from the completed phase 3 SOLARIS trial at the 2025 Psych Congress Annual Meeting, taking place from September 17 – 21, 2025, in San Diego, California. Teva will also host a conference call for analysts and investors on Monday, September 22, 2025, at 11:00 a.m. ET to discuss these data. In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. To access a live webcast of the presentation, visit Teva's Investor Relations website at https://ir.tev

    9/16/25 4:30:00 PM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADCT
    $CTOR
    $ONCY
    $OSTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by ADC Therapeutics SA

    SC 13G/A - ADC Therapeutics SA (0001771910) (Subject)

    11/14/24 9:00:57 PM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by ADC Therapeutics SA

    SC 13G/A - ADC Therapeutics SA (0001771910) (Subject)

    11/13/24 8:58:56 AM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by ADC Therapeutics SA

    SC 13G/A - ADC Therapeutics SA (0001771910) (Subject)

    11/13/24 8:30:55 AM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care